Área Técnica: Retina
SHORT-TERM VARIATION OF MACULAR THICKNESS AFTER INTRAVITREAL BEVACIZUMAB INJECTION FOR DIABETIC MACULAR EDEMA
To evaluate the short-term variation of central macular thickness (CMT) after intravitreal bevacizumab injection for diabetic macular edema
A prospective observational clinical study was performed. Written informed consent was obtained for every patient. Study was approved by the Ethics Committee number 35463914.2.0000.0088. Trial was registered at EudraCT number 2015-005516-15. Assessment for best corrected visual acuity (BCVA) was performed at baseline and 24 hours, 3 days, 7 days, 14 days, 21 days, and 28 days after intravitreal injection of bevacizumab. The patient was evaluated including fundus biomicroscopy and optical coherence tomography central macular thickness using Spectralis (Heidelberg Engineering) at baseline and 1 hour, 4 hours, 24 hours, 3 days, 7 days, 14 days, 21 days, and 28 days after intravitreal injection of bevacizumab.
A total of 16 eyes of 12 patients (6 male; mean age, 62 ± 8.7 years; range, 50-74 years) who completed the 28-day follow-up were included for analysis. Mean CMT at baseline was: 551 ± 219.38μm; Mean CMT at 1 hour, 4- hour, 24-hour, 3-day, 7 day, 14-day, 21-day, and 28-day were: 543 ± 217μm, 531 ± 217μm, 505 ± 189μm, 473 ± 153μm, 475 ± 150μm, 453 ± 137μm, 466 ± 169μm, and 465 ± 164μm, respectively. Statistically significant reduction of CMT compared to baseline was found at the 4-hour follow-up (mean CMT reduction: t=3.6389, p < 0.01), and lasted until the 28-day follow-up (mean CMT reduction: t=2.1453, p < 0.05). Improvement in mean BCVA was observed in the 24-hour follow-up and lasted until the 28-day follow-up although it was not statistically significant.
Bevacizumab produced improvement in CMT as soon as 4-hour after injection that persists up to 28 days. However, visual acuity did not reached statistical significance level, probably due to the sample size.